Fold the future
At Sibylla Biotech, we face the complexity of drug discovery with the power of an innovative computational approach to tackle unmet medical needs.
Sibylla’s platform leverages on the enabling breakthrough of simulating protein folding pathways to unveil a new class of small-molecule degraders. Such compounds trigger the degradation of the target protein by interfering with its folding pathway.
By exploiting this new paradigm that we named “Pharmacological Protein Inactivation by Folding Intermediates Targeting” (PPI-FIT), Sibylla can identify and develop small molecules acting on targets involved in different types of diseases. Indeed, PPI-FIT is applicable to any therapeutic area.
Sibylla’s biology lab test and characterize folding interfering degraders. Promising compounds are then optimized and developed by relying on structure-based and ligand-based rational drug design approaches.